Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer
https://doi.org/10.21518/2079-701X-2018-19-50-55
Abstract
Colorectal cancer (CRC) is a genetically heterogeneous disease, which prognosis and efficacy of treatment are determined by the localization of the primary tumour (left- and right-sided tumours). CRC ranks high in prevalence in the Russian Federation, a quarter of cases are diagnosed at stage IV. The choice of the most optimal therapy regimen is a topical issue for a modern oncologist, who has time-proven combinations of chemotherapy and modern targeted drugs in the arsenal. The aim of this article is to provide a pharmacoeconomic review, taking into account both clinical and economic parameters of one or another CRC pharmacotherapy regimen. As a result, it was found that the use of chemotherapeutic regimens in the first- and second-line therapies of patients with CRC is the most pharmacoeconomically justified as compared with the use of targeted therapy at the initial stage.
About the Authors
A. A. Tryakin
Blokhin Russian Cancer Research Center of the Ministry of Health of Russia
Russian Federation
Russian Federation
P. A. Balunov
REMEDIUM GROUP Ltd
Russian Federation
Russian Federation
References
1. Lindsey A. Torre MSPH. Global cancer statistics, 2012. CA Cancer J Clin, 2015 March/April, 65(2): 87–108.
2. Kaprin AD, Starinsky VV. Malignant neoplasms in Russia in 2017. M.: Hertsen Moscow Oncology Research Center – a branch of the Federal Research Center of Radiology of the Ministry of Health of Russia, 2018.
3. Fedorov VE, Podelyakin KA. Epidemiological aspects of colorectal cancer (review). Meditsinskiy Almanakh, 2017 September, 4 (49): 145-148
4. Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Annals of Oncology. Published online 12 April 2017.
5. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209-1214.
6. Venook AP, Niedzwiecki D, Innocenti F et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mcrc): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol, 2016, 34(suppl.): abstr. 3504.
7. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008, 26: 374-379.
8. Douillard JY, Oliner KS, Siena S et al. Panitumu mabFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369: 1023-1034.
9. Fedyanin MYu. Modern clinical and molecular biological platform for the treatment of patients with colon cancer. Dissertation. M., 2017.
10. Douillard JY. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010 Nov 1, 28(31): 4697-4705.
11. Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G,Siena S, Tabernero J, Douillard J-Y, André T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology, 2017 August 1, 28(Issue 8): 1862–1868.
12. Tejpar S. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol, 2016 Oct 10.
13. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011, 29: 2011– 2019.
14. Loupakis F, Yang D, Yau L et al. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute, 2015, 107(3): dju427. Doi:10.1093/jnci/dju427.
15. Cassidy J. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 2011 Jun 28, 105(1): 58-64.
16. Giantonio BJ. Bevacizumab in Combination WithOxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 2007, 25(12): 1539-1544.
17. Van Cutsem E. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an OxaliplatinBased Regimen. Journal of Clinical Oncology, 2012, 30(28): 3499-3506.
18. Fedyanin MYu, Aliyeva ShA, Vladimirova LYu, Ivanov AN, Katkov AA, et al. The quality of antitumor treatment in patients with metastatic colon cancer in routine clinical practice. Zlokachestvennye Opukholi. Special Issue 1, 2017, 7 (3): 4-11.
Review
For citations:
Tryakin AA, Balunov PA. Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer. Meditsinskiy sovet = Medical Council. 2018;(19):50-55. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-50-55
Views:
749
Email this article 